Transmitted and Acquired HIV-1 Drug Resistance from a Family: A Case Study

Yan, Liting; Yu, Fang; Zhang, Huimin; Zhao, Hongxin; Wang, Linghang; Liang, Zaiyan; Xia, Zhengyuan; Wu, Liang; Hu, Liang; Yang, Siyuan; Tang, Yuling; Zhang, Fujie

doi:10.2147/idr.s272232

Cited by 5 publications

(3 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meanwhile, consistent with previous studies, NGS can detect more low-frequency mutations that are missed by Sanger sequencing. 18 , 27 But the clinical consequences of low-frequency mutations detected by NGS are still controversial. Studies have shown that NNRTI-related low-frequency resistance mutations are closely related to VF.…”

Section: Discussionmentioning

confidence: 99%

“…Next-generation sequencing (NGS) has improved the ability of quantitative identification of minority resistant variants (MRVs). 18 , 19 However, few studies have focused on the application of NGS technology on TDR mutations of INSTIs. Therefore, the aim of this study was to monitor the prevalence of INSTIs-related drug resistance mutations among ART-naive patients in Beijing and to explore the Clinical implications of NGS for detecting MRVs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China

Yuan¹,

Q²,

Wang³

et al. 2022

PGPM

Self Cite

View full text Add to dashboard Cite

Introduction Integrase strand transfer inhibitors (INSTIs) are important drugs that are currently used as the first line treatment for HIV-1 patients. The aim of this study was to characterize HIV-1 INSTI mutations among ART-naive patients in Beijing from 2019–2021. Methods 865 ART-naive patients were enrolled in this study between January 2019 and June 2021 in Beijing. The amplification of the entire pol gene containing the reverse transcriptase, protease and integrase regions was performed using a validated In-house SBS method. HIV-1 subtypes and circulating recombinant forms (CRFs) were determined using the COMET online tool ( http://comet.retrovirology.lu ). Stanford HIV-1 drug resistance database (HIVdb version 8.9) was used to analyze the mutations. Results 865 HIV-1 pol sequences were successfully amplified and sequenced. Among them, no major INSTI-related mutations were identified, but 12 polymorphic accessory mutations were found. Two patients have E138A and G163R mutations respectively and both could cause low-level resistance to RAL and EVG. Furthermore, one patient having S230R mutation resulted in low-level resistance to RAL, EVG, DTG and BIC. Conclusion The prevalence of INSTIs mutations remains low, which demonstrated that INSTIs have good applicability currently in our city. Nevertheless, it is very important to monitor the INSTI-related mutations in Beijing.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China

Yuan¹,

Q²,

Wang³

et al. 2022

PGPM

Self Cite

View full text Add to dashboard Cite

show abstract

“…The inadequate management of HIV infections has been mainly attributed to the lack of accessibility, expensiveness, and the inability of drugs. Apart from these factors, drug resistance in patients receiving antiretroviral therapy (ART) has also played a major role in the global expansion of HIV infections [ 5 ]. Out of two types of HIV (HIV-1 and HIV-2), HIV-1 is the most prevalent, and potent, and is considered the main reason for AIDS progression around the globe [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Employing computational tools to design a multi-epitope vaccine targeting human immunodeficiency virus-1 (HIV-1)

Sher,

Sharif,

Zaheer

et al. 2023

BMC Genomics

View full text Add to dashboard Cite

Background Despite being in the 21st century, the world has still not been able to vanquish the global AIDS epidemic, and the only foreseeable solution seems to be a safe and effective vaccine. Unfortunately, vaccine trials so far have returned unfruitful results, possibly due to their inability to induce effective cellular, humoral and innate immune responses. The current study aims to tackle these limitations and propose the desired vaccine utilizing immunoinformatic approaches that have returned promising results in designing vaccines against various rapidly mutating organisms. For this, all polyprotein and protein sequences of HIV-1 were retrieved from the LANL (Los Alamos National Laboratory) database. The consensus sequence was generated after alignment and used to predict epitopes. Conserved, antigenic, non-allergenic, T-cell inducing, B-cell inducing, IFN-ɣ inducing, non-human homologous epitopes were selected and combined to propose two vaccine constructs i.e., HIV-1a (without adjuvant) and HIV-1b (with adjuvant). Results HIV-1a and HIV-1b were subjected to antigenicity, allergenicity, structural quality analysis, immune simulations, and MD (molecular dynamics) simulations. Both proposed multi-epitope vaccines were found to be antigenic, non-allergenic, stable, and induce cellular, humoral, and innate immune responses. TLR-3 docking and in-silico cloning of both constructs were also performed. Conclusion Our results indicate HIV-1b to be more promising than HIV-1a; experimental validations can confirm the efficacy and safety of both constructs and in-vivo efficacy in animal models. Graphical Abstract

show abstract

Efavirenz/lamivudine/tenofovir-disoproxil-fumarate

2021

Reactions Weekly

View full text Add to dashboard Cite

Transmitted and Acquired HIV-1 Drug Resistance from a Family: A Case Study

Cited by 5 publications

References 37 publications

Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China

Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China

Employing computational tools to design a multi-epitope vaccine targeting human immunodeficiency virus-1 (HIV-1)

Efavirenz/lamivudine/tenofovir-disoproxil-fumarate

Contact Info

Product

Resources

About